Apogenix GmbH

  • Biotech or pharma, therapeutic R&D

We are a clinical stage, single asset company. Our drug asset asunercept/APG101 is a Fc fusion protein that is ready for phase II in lower risk myelodysplastic syndromes (MDS) and has already achieved proof-of-concept in MDS (phase I/II), rGBM (phase II) and COVID-19 (phase III stopped). 20.000 doses in stock to start the phase II upon funding.

Address

Heidelberg
Germany

Website

https://www.apogenix.com

Contact Exhibitor


Loading
View all Partnering Companies

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS